NeuroPace (NPCE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting commenced at 10:31 A.M. PDT on June 5, 2026, with introductions of board and leadership team members, and the agenda outlined for the session.
Voting procedures and meeting rules were explained, including instructions for submitting questions and the order of business.
Board and executive committee updates
Two director nominees, Lisa Andrade and Scott Huennekens, were presented for election to serve until the 2029 annual meeting.
Corporate governance
Anna Hagberg-Szeto was appointed as Inspector of Election, taking an oath to ensure impartiality in vote tallying.
Confirmation of proper notice to stockholders and verification of a quorum with proxies for 86% of outstanding shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NeuroPace
- Q2 2026 revenue up 17% to $22.8M, margins improved, and guidance raised as FDA review continues.NPCE
Q2 2026 - FDA requests more data for RNS System IGE expansion but sees a collaborative path to approval.NPCE
FDA announcement - Targeting 20%+ CAGR through 2027 with new indications, AI tools, and expanded market access.NPCE
Investor Day 2025 - Q1 2026 revenue up 20% to $22.1M; guidance raised, with strong RNS and AI momentum.NPCE
Q1 2026 - Vote on two director nominees and auditor ratification at the June 2026 virtual annual meeting.NPCE
Proxy filing - Proxy covers director elections, auditor ratification, and robust governance and compensation policies.NPCE
Proxy filing - 2026 is set to be a pivotal year, driven by new indications, AI tools, and expanding market reach.NPCE
25th Annual Needham Virtual Healthcare Conference - Strong 2025 growth and margin gains set the stage for transformational expansion in 2026.NPCE
Q4 2025 - Q3 revenue up 28% YoY to $21.1M, net loss narrows, and 2024 guidance raised on RNS growth.NPCE
Q3 2024